COIOSDeep risk insights through multi-disciplinary research across the globe
silhouette of city buildings during sunset
Item new Peer-reviewed Added

Modelled hepatitis B cure is cost-effective under USD46,642 a course in the US

A Markov model estimated that a hepatitis B cure regimen working in 30% of patients would be cost-effective at a one-off price below USD46,642 in the US.

A Markov model compared a hypothetical cure regimen working in 30% of patients with indefinite nucleos(t)ide analogue therapy for chronic hepatitis B. In a 50-year-old man with non-cirrhotic disease and suppressed virus, the regimen gained 0.30 quality-adjusted life years in the US and 0.57 in China. It would be cost-effective at a one-off cost below USD46,642 in the US and USD13,008 in China.

Why it is interesting: A price ceiling set for a regimen that does not yet exist, and it differs by country.

Source
Clinical and Translational Gastroenterology, 28 September 2026
Paper
A Markov model cost threshold analysis of potential hepatitis B virus cure regimens
Authors
Wong GL, Wong RJ, Yang B, Wong VW, Lai JC, Chan HL et al.
DOI
10.14309/ctg.0000000000001108
Type
Peer-reviewed article
Design
Markov state-transition cost-utility model, base case 50-year-old HBeAg-negative non-cirrhotic man on suppressive NUC, US and China cost perspectives
Verdict
New finding
Driver
Value in health
Free full text
Free to read at the publisher

Other drivers in Data, models and systems